Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2450 + anlotinib hydrochloride + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of TQB2450 (benmelstobart), a humanized monoclonal antibody targeting PD-L1; anlotinib hydrochloride, a multi-targeted tyrosine kinase inhibitor with anti-angiogenic properties; and the chemotherapy combination of oxaliplatin and capecitabine (known as CAPOX or XELOX). This regimen combines immunotherapy, anti-angiogenic therapy, and chemotherapy approaches, potentially offering synergistic effects in cancer treatment.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)FGFR (FGFR family)TS (Thymidylate synthase)PDGFRA (Platelet-derived growth factor receptor alpha)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on TQB2450 + anlotinib hydrochloride + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2450 + anlotinib hydrochloride + oxaliplatin + capecitabine.